Dr Nishidaa and colleagues conducted a retrospective study of 1058 liver transplant recipients.
The research team determined the incidence, etiology, timing, clinical features and treatment of refractory ascites.
|Survival following refractory ascites was poorer with Hep C recurrence|
|American Journal of Liver Transplantation|
The researchers established the risk factors for refractory ascites development, and the predictors of refractory ascites disappearance.
In addition, the team assessed the predictors of survival following refractory ascites, and the impact of refractory ascites on patient survival.
The team consulted 62 patients that had developed refractory ascites, and noted that its disappearance occurred in 27 cases.
Patients having Hepatitis C virus had a significantly higher hazard rate of developing refractory ascites.
The team reported that no other baseline characteristic was associated with refractory ascites.
The researchers undertook a stepwise regression analysis of the hazard rate of refractory ascites disappearance.
Following this analysis, the team found 2 significant factors contributed to developing refractory ascites.
The team noted that Hepatitis C virus recurrence implied a poorer outcome, whereas an unknown reason implied a favourable outcome.
In addition, survival following refractory ascites was significantly poorer among patients having bacterial peritonitis or Hepatitis C virus recurrence.
The mortality rate was 9 times higher in patients following refractory ascites development, while it was ongoing.
The researchers found that if the refractory ascites disappeared, then the additional risk of death also disappeared.”
Dr Nishidaa's team concluded, “This study illustrates the importance of developing an optimal treatment strategy to effectively treat refractory ascites if it develops and to prevent Hepatitis C recurrence.”